The United Kingdom and the United States have finalized a landmark bilateral deal that will preserve no duties on British drug shipments being sold in the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to increase funding on medicines through the NHS. This commitment ensures that import taxes on these vital exports will stay at zero for a period of three years.
This agreement is in response to previous threats to significantly raise import taxes on patented pharmaceutical products, with increases mentioned as high as 100%.
"This agreement with the UK reinforces the global environment for cutting-edge drugs and establishes long-overdue fairness to American-British drug exports," a statement noted.
Trade Significance
Pharmaceuticals are one of the the United Kingdom's largest exports to the United States, which is clearly the largest buyer for leading British pharmaceutical firms.
Export figures reveal that in the 12 months prior to September, the UK exported pharmaceutical products worth billions to the US. This value made up 17.4% of total UK exports in that span.
"This guarantee safeguards employment, increases investment and paves the way for the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary stated.
Key NHS Changes
The agreement includes several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a goal to double total NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the next decade.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to control costs will be restricted at fifteen percent. In the past, rebates were more than 20%.
Broader Context
The deal takes place against a ongoing dispute between the sector and the ministers over drug pricing and approval rates.
The disagreement were heightened by assertions that American consumers were charged a premium for the equivalent treatments than consumers in the UK and Europe.
In recent months, several large drug company projects in the UK have been paused or abandoned, while major expansions have been announced toward American operations.
A senior figure acknowledged that the NHS must spend more on treatments, noting that its budget allocation on drugs had declined as a share of its overall budget over the previous ten-year period.
